Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

5Total

Not Applicable (3)

Early P 1 (2)

Trial Status

Completed2

Enrolling By Invitation1

Recruiting1

Withdrawn1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (5)

Showing 5 of 5 trials

NCT05995626Early Phase 1CompletedPrimary

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT06801535Not ApplicableRecruitingPrimary

Efficacy of 3D-Printed Mouth Splints

NCT07264218Not ApplicableEnrolling By Invitation

Clinical Effectiveness of a Patient-tailored Orthosis Based on 3-dimensional (3D) Scanner Modeling and 3D Printing Technology for Microstomia Caused by Burns : Pilot Study

NCT04656704Early Phase 1WithdrawnPrimary

Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease

NCT04336475Not ApplicableCompletedPrimary

The Effect of a Home-based Orofacial Exercise Program on Oral Aperture of Systemic Sclerosis Patients

Showing all 5 trials

Microstomia